Download PDF
J Neurol Surg B Skull Base 2015; 76(03): 208-213
DOI: 10.1055/s-0034-1543995
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Predictors of Survival in Sinonasal Adenocarcinoma

Michelle M. Chen
1   Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, United States
,
Sanziana A. Roman
2   Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States
,
Julie A. Sosa
2   Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States
3   Endocrine Neoplasia Diseases Group, Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States
,
Benjamin L. Judson
4   Section of Otolaryngology, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, United States
› Author Affiliations
Further Information

Publication History

26 March 2014

16 June 2014

Publication Date:
05 January 2015 (online)

    Permissions and Reprints

Abstract

Objectives To identify factors associated with disease-specific survival (DSS) in intestinal and nonintestinal sinonasal adenocarcinoma.

Design Retrospective review.

Setting Surveillance Epidemiology and End Results database.

Participants Adult patients with sinonasal adenocarcinoma.

Main Outcome Measures DSS.

Results We identified 325 patients; of these, 300 had the nonintestinal type and 25 had intestinal type histologies. The 5-year DSS rates for patients who had no treatment, radiation (RT), surgery, and surgery and postoperative RT were 42.5, 46.1, 85.6, and 72.6%, respectively (log-rank test; p < 0.001). Black race, age ≥ 75 years, paranasal sinus involvement, and high grade were independently associated with decreased DSS. Compared with RT, surgery (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.15–0.77), and adjuvant RT (HR: 0.47; 95% CI, 0.26–0.86) were associated with improved DSS.

Conclusions There is no difference in prognosis between intestinal and nonintestinal subtypes of sinonasal adenocarcinoma. Treatment with surgery alone or adjuvant RT is associated with a more favorable prognosis.

Keywords

sinonasal - adenocarcinoma - intestinal type - nonintestinal type - survival
 

  • References

  • 1 Ganly I, Patel SG, Singh B , et al. Craniofacial resection for malignant paranasal sinus tumors: report of an International Collaborative Study. Head Neck 2005; 27 (7) 575-584
    CrossrefPubMedGoogle Scholar
  • 2 International Academy of Pathology, World Health Organization, International Agency for Research on Cancer. Pathology and Genetics of Head and Neck Tumours. Lyon, France: IARC Press; 2005
    Google Scholar
  • 3 Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34 (6) 877-885
    CrossrefPubMedGoogle Scholar
  • 4 Haerle SK, Gullane PJ, Witterick IJ, Zweifel C, Gentili F. Sinonasal carcinomas: epidemiology, pathology, and management. Neurosurg Clin N Am 2013; 24 (1) 39-49
    CrossrefPubMedGoogle Scholar
  • 5 Luce D, Leclerc A, Bégin D , et al. Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes Control 2002; 13 (2) 147-157
    CrossrefPubMedGoogle Scholar
  • 6 Bhayani MK, Yilmaz TA, Sweeney A , et al. Sinonasal adenocarcinoma: a 16-year experience at a single institution. Head Neck 2014; . Available at: http://onlinelibrary.wiley.com/doi/10.1002/hed.23485/pdf . Accessed January 5, 2014
    PubMedGoogle Scholar
  • 7 Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A. Prognostic factors in sinonasal tumors involving the anterior skull base. Head Neck 2004; 26 (2) 136-144
    CrossrefPubMedGoogle Scholar
  • 8 Heffner DK, Hyams VJ, Hauck KW, Lingeman C. Low-grade adenocarcinoma of the nasal cavity and paranasal sinuses. Cancer 1982; 50 (2) 312-322
    CrossrefPubMedGoogle Scholar
  • 9 Shah JP, Kraus DH, Bilsky MH, Gutin PH, Harrison LH, Strong EW. Craniofacial resection for malignant tumors involving the anterior skull base. Arch Otolaryngol Head Neck Surg 1997; 123 (12) 1312-1317
    CrossrefPubMedGoogle Scholar
  • 10 National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program brochure. Available at: http://seer.cancer.gov/about/factsheets/SEER_brochure.pdf . Accessed September 13, 2013
    PubMedGoogle Scholar
  • 11 Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92 (12) 3012-3029
    CrossrefPubMedGoogle Scholar
  • 12 Lund VJ, Stammberger H, Nicolai P , et al; European Rhinologic Society Advisory Board on Endoscopic Techniques in the Management of Nose, Paranasal Sinus and Skull Base Tumours. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 2010; (22) 1-143
    PubMedGoogle Scholar
  • 13 Sanghvi S, Khan MN, Patel NR, Yeldandi S, Baredes S, Eloy JA. Epidemiology of sinonasal squamous cell carcinoma: a comprehensive analysis of 4994 patients. Laryngoscope 2014; 124 (1) 76-83
    CrossrefPubMedGoogle Scholar
  • 14 Ragin CC, Langevin SM, Marzouk M, Grandis J, Taioli E. Determinants of head and neck cancer survival by race. Head Neck 2011; 33 (8) 1092-1098
    CrossrefPubMedGoogle Scholar
  • 15 Harlan LC, Hankey BF. The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 2003; 21 (12) 2232-2233
    CrossrefPubMedGoogle Scholar
  • 16 Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76 (11) 2343-2350
    CrossrefPubMedGoogle Scholar
  • 17 Trinkaus ME, Coleman A, D'Costa I, Sigston E, Rischin D. Recurrent intestinal type sinonasal adenocarcinoma treated with FOLFOX6 chemotherapy: case report and review of literature. Int J Case Rep Images 2012; 3 (8) 17-20
    PubMedGoogle Scholar
  • 18 Licitra L, Suardi S, Bossi P , et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 2004; 22 (24) 4901-4906
    CrossrefPubMedGoogle Scholar